Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: Relevance to sickle cell disease

Pharmacogenetics and Genomics

Volumn 20, Issue 4, 2010, Pages 257-263

  Laurance, Sandrine ^a,b   Pellay, François Xavier ^c,d   Dossou Yovo, Orner P ^a,b   Verger, Emmanuelle ^a,b   Krishnamoorthyb, Rajagopal ^a,b   Lapoumeroulie, Claudine ^a,b   Benecke, Arndt ^c,d   Elion, Jacques ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT DES HAUTES ÉTUDES SCIENTIFIQUES   (France)

^d CNRS   (France)

Author keywords

Hydroxycarbamide; Inflammation; Sickle cell disease; Transcriptome; Vascular endothelial cells

Indexed keywords

HYDROXYUREA; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES; TRANSCRIPTOME;

ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MICROCIRCULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SICKLE CELL; UPREGULATION; VASCULAR ENDOTHELIUM;

EID: 77950639333     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833854d6     Document Type: Article

References (40)

1. Beihassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001 ; 97:1584-1589. (Pubitemid 32217221)
2. Elion JE, Brun M, Odievre MH, Lapoumeroulle CL, Krlshnamoorthy R. Vasoocclusion in sickle cell anemia: role of interactions between blood cells and endothelium. Hematol J 2004; 5 (Suppl 3):S195-S198. (Pubitemid 39077304)
3. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 2002; 9:101-106.
4. Hebbel RP, Osaroglagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004; 11:129-151. (Pubitemid 39619075)
5. PiattOS.Sicklecellanemiaasaninflammatorydisease.JClinInvest2000;106: 337-338.(Pubitemid30655633)
6. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes In sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000; 96:2451-2459.
7. PiattOS,BramblllaDJ,RosseWF,MilnerPF,CastroO,SteinbergMH,etal. Mortalityinsicklecelldisease.Lifeexpectancyandriskfactorsforearlydeath. NEnglJMed1994;330:1639-1644.(Pubitemid124005049)
8. CroizatH.CirculatingcytokinesInsicklecellpatientsduringsteadystate. BrJHaematol1994;87:592-597.(Pubitemid24230028)
9. Etienne-JulanM,BelloyMS,DecastelM,DougaparsadS,RavionS,HardyDessourcesMD. Childhoodsicklecellcrises:clinicalseverity, inflammatorymarkersandtheroleofinterleukin-8.Haematologica2004;89:863-864. (Pubitemid38981348)
10. Francis RB Jr, Haywood LJ. Elevated immunoreactlve tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 1992; 84:611-615.
11. Charache S, Terrln ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317-1322.
12. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289:1645-1651.
13. Maier-Redelsperger M, de Montalembert M, Flahault A, Neonato MG, Ducrocq R, Masson MP, et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood 1998; 91:4472-4479.
14. HilleryCA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and lamlnin. Sr J Haematol 2000; 109:322-327.
15. AdragnaNC,FonsecaP,LaufPK.Hydroxyureaaffectscellmorphology, cationtransport,andredbloodcelladhesioninculturedvascularendothelialcells. Blood1994;83:553-560.(Pubitemid24030584)
16. StylesLA,LublnB,VichinskyE,LawrenceS,HuaM,TestS,etal. Decreaseofverylateactivationantlgen- 4andCD36onreticulocytesinsicklecellpatientstreatedwithhydroxyurea.Blood1997;89: 2554-2559.(Pubitemid27143305)
17. Odievre MH, Bony V, Benkerrou M, Lapoumeroulie C, Alberti C, Ducrocq R, etal. Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica 2008; 93:502-510. (Pubitemid 351536377)
18. Brun M, Bourdoulous S, Couraud PO, Elion J, Krlshnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J 2003; 3:215-226. (Pubitemid 37160977)
19. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea Induces the eNOS-cGMP pathway In endothelial cells. Blood2006; 108:184-191.
20. LapoumeroulieC,BenkerrouM,OdievreMH,DucrocqR,BrunM,ElionJ. Decreasedplasmaendothelln- 1levelsinchildrenwithsicklecelldiseasetreatedwithhydroxyurea. Haematologica2005;90:401-403.(Pubitemid40388991)
21. SchweitzerKM,VicartP,DelouisC,PaulinD,DragerAM,LangenhuijsenMM,efal. Characterizationofanewlyestablishedhumanbonemarrowendothelialcellline: distinctadhesivepropertiesforhematopoietic progenitorscomparedwithhumanumbilicalveinendothelialcells.LabInvest1997;76: 25-36.(Pubitemid27058195)
22. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52:2745-2756.
23. Chomczynskl P, Sacchi N. Single-step method of RNA Isolation by acid guanidlnium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159. (Pubitemid 17064313)
24. Noth S, Brysbaert G, Pellay FX, Benecke A. High-sensitivity transcriptome data structure and implications for analysis and biologic interpretation. Genomics Proteomics Bioinformatics 2006; 4:212-229. (Pubitemid 46771386)
25. Noth S, Brysbaert G, Benecke A. Normalization using weighted negative second order exponential error functions (NeONORM) provides robustness against asymmetries in comparative transcriptome profiles and avoids false calls. Genomics Proteomics Bioinformatics 2006; 4:90-109. (Pubitemid 44247935)
26. Noth S, Benecke A. Avoiding inconsistencies over time and tracking difficulties in Applied Biosystems AB1700/Panther probe-to-gene annotations. BMC Bioinformatics 2005; 6:307. (Pubitemid 43046106)
27. Zachlederova M, Jarolim P. Gene expression profiles of microvascular endothelial cells after stimuli implicated In the pathogenesis of vasoocclusion. Blood Cells Mol Dis 2003; 30:70-81. (Pubitemid 36378868)
28. MatsushimaK,CopelandTD,OnozaklK,OppenheimJJ. Purificationandbiochemicalcharacteristic softwodistincthumaninterleukins1fromthemyeloomonocyticTHP-1cellline. Biochemistry1986;25:3424-3429.(Pubitemid16056979)
29. Pal K, Shrivastava A, Kumar R, Khetarpal S, Sarmah B, Gupta P, ef al. Activation of P388D1 macrophage cell line by chemotherapeutic drugs. Life Sci 1997; 60:1239-1248. (Pubitemid 27191763)
30. Heredia A, Davis C, Amoroso A, Dominique JK, Le N, Klingebiel E, ef a/. Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R6 HIV-1. Proc Natl Acad Sci USA 2003; 100:4179-4184. (Pubitemid 36418177)
31. Coklc VP, Smith RD, Beleslln-Coklc BB, Njoroge JM, Miller JL, Gladwin MT, ef al. Hydroxyurea Induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003; 111:231-239. (Pubitemid 36105922)
32. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response In liver cells. Proc Natl Acad Sci USA 1987; 84:7251-7255.
33. Dinarello CA. lnterleukin-1 and ¡nterleukin-1 antagonism. Blood 1991; 77:1627-1652.
34. Romano M, Sironl M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:315-325.
35. BaconKB,Flores-RomoL,AubryJP,WellsTN,PowerCA.lnterleukln- 8andRANTESinducetheadhesionofthehumanbasophiliccelllineKU-812- humanendothelialcellmonolayers.Immunology1994;82:473-481.(Pubitemid2104649)
36. Bagglolinl M, lmboden P, Detmers P. Neutrophil activation and the effects of interleukln-8/neutrophil-activating peptide 1 (IL-8/NAP-1). Cytokines 1992;4:1-17.
37. Ataga Kl, Moore CG, Hillary CA, Jones S, Whinna HC, Strayhorn D, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008; 93:20-26. (Pubitemid 351156147)
38. NavarraP,GrohmannU,NocentiniG,TringaliG,PuccettiP,RiccardiC,efal. Hydroxyureainducesthegeneexpressionandsynthesisofproinflammatorycytokinesinvivo. JPharmacolExpTher1997;280:477-482.(Pubitemid27171437)
39. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immunemediated Inflammation. N Engl J Med 1995; 332:1351-1362.
40. Navarra P, Tringali G, Preziosi P. Hydroxyurea Influences adrenocortical function In humans. Eur J Clin Pharmacol 1998; 54:491-492 (Pubitemid 28418819)